<DOC>
	<DOC>NCT00817414</DOC>
	<brief_summary>This study will determine the maximum dose of LCI6999 with respect to effect on the ACTH-stimulated cortisol response in patients with hypertension</brief_summary>
	<brief_title>An Evaluation of the Effects of LCI699 on Cortisol in Patients With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<criteria>Diagnosis of hypertension with blood pressure â‰¥ 140/90 mmHg and &lt; 180/110 mmHg on current antihypertensive treatment Male and female patients 1875 years of age Subjects must weigh at least 50 kg Recent history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebral accident or transient ischemic attack Clinically significant ECG findings related to cardiac conduction defects Type 1 diabetes or uncontrolled type 2 diabetes (HbA1c &gt; 9%) Malignancies within the last 5 years (excluding basal cell skin cancer) Liver disease Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Blood Pressure</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Cortisol</keyword>
</DOC>